PeptideForward
Peptide therapy, done properly

Peptide care, guided by licensed providers.

Compare evidence-based peptide therapies and get matched with vetted telehealth clinicians who can determine whether treatment is right for you, all prescribed and compounded through legitimate channels.

PeptideForward may earn a referral fee if you connect with a provider through us, at no extra cost to you. Learn more

20+peptides & GLP-1s
100%licensed prescribers
~5 mineligibility check

How matching works

No cost to see if you qualify.

1
Answer a few health questions

Goals, history, and what you're hoping to address.

2
A licensed provider reviews

A clinician evaluates whether therapy is appropriate.

3
Get matched & treated

If eligible, your provider prescribes through a compounding pharmacy.

Start the eligibility check
The process

From question to care in four steps

01

Tell us your goals

Recovery, metabolic health, longevity, or sleep, a short intake captures what matters to you.

02

Clinical review

A licensed healthcare provider reviews your information and history to assess candidacy.

03

Personalized plan

If appropriate, your provider prescribes a protocol filled by a licensed compounding pharmacy.

04

Ongoing support

Adjust dosing, refill, or message your care team whenever you need to.

The library

Explore the peptides people are asking about

Plain-language guides on what each peptide is, how it's studied, and its current regulatory status in the United States.

Explore all 20 peptide guides →
2026 regulatory update

The landscape is shifting in July

A federal advisory committee is meeting on July 23–24, 2026 to consider whether a group of peptides should be added back to the list of substances licensed pharmacies may compound. We track every development so you understand what it means for legitimate access.

Read the full tracker →
Live timeline
  • Feb 2026Federal officials signal intent to expand lawful compounding access for ~14 peptides.
  • Apr 2026FDA publishes notice scheduling an advisory committee meeting and updates its bulk-substances list.
  • Jul 23–24Advisory committee meets to consider recommendations for the compounding list.
  • AfterAny change requires formal rulemaking, we'll update this timeline as it develops.
Where things stand today

Current legal status, in plain terms

Not every peptide sits in the same place legally. Here's the honest breakdown, because some sites blur these lines, and getting it right protects you.

● Available now

FDA-approved drugs

Fully legal today with a prescription from a licensed provider. No need to wait on any ruling.

Includes: Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, Tesamorelin, PT-141
● Compounded

Prescribable via pharmacies

Legal when prepared by licensed 503A/503B pharmacies under a valid prescription. A narrowing space, provider-dependent.

Includes: Sermorelin, and certain compounded formulations under provider guidance
● Under 2026 review

In FDA evaluation

Not yet confirmed for legal compounding. Pending the July advisory meeting and formal rulemaking, remain prescription-only even if reclassified.

Includes: BPC-157, TB-500, CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and others

Some clinics market under-review peptides as "legal again." As of today, the formal FDA rule has not published, and compounds like BPC-157 remain in the evaluation process. We update this as developments are confirmed.

Why PeptideForward

Every provider we match you with is licensed.

We don't sell products and we're not a pharmacy. We help you understand your options and connect you with vetted telehealth clinicians who prescribe through legitimate, regulated channels, never the gray market.

Get matched with a provider →

PeptideForward may earn a referral fee if you connect with a provider through us, at no extra cost to you. Learn more

Stay informed

Get the July ruling in your inbox

One email when the advisory committee decides, plus plain-language updates on what changes for patients. No spam.